Cargando…
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma
Gamma-glutamyltransferase (GGT) is an established marker for proliferative/apoptotic balance and has been associated with cancer risk and prognosis. The aim of this study was to evaluate the value of pre-treatment GGT serum levels as prognostic biomarker in patients with primary uterine leiomyosarco...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028736/ https://www.ncbi.nlm.nih.gov/pubmed/27646551 http://dx.doi.org/10.1038/srep33757 |
_version_ | 1782454386598871040 |
---|---|
author | Schwameis, Richard Grimm, Christoph Brodowicz, Thomas Petru, Edgar Hefler-Frischmuth, Katrin Staudigl, Christine Reinthaller, Alexander Heinze, Georg Polterauer, Stephan Polterauer, Mariella |
author_facet | Schwameis, Richard Grimm, Christoph Brodowicz, Thomas Petru, Edgar Hefler-Frischmuth, Katrin Staudigl, Christine Reinthaller, Alexander Heinze, Georg Polterauer, Stephan Polterauer, Mariella |
author_sort | Schwameis, Richard |
collection | PubMed |
description | Gamma-glutamyltransferase (GGT) is an established marker for proliferative/apoptotic balance and has been associated with cancer risk and prognosis. The aim of this study was to evaluate the value of pre-treatment GGT serum levels as prognostic biomarker in patients with primary uterine leiomyosarcoma (ULMS). Data of women with ULMS were extracted from a multi-center database. Pre-treatment GGT serum levels were measured and patients assigned to predefined GGT risk groups. GGT values were correlated with clinico-pathological parameters and univariate and multivariable survival analyses were performed. A total of 44 patients with ULMS were analyzed. Mean (SD) pre-therapeutic GGT serum level was 33.8 (39.8) U/L. In Figo Stage I versus II-IV mean (SD) GGT values were 28.8 (34.0) U/l and 43.5 (49.2) U/l, respectively (p = 0.25). Five-year overall survival (OS) rates in ULMS patients with normal low versus higher GGT levels were 70% and 37%, respectively (p = 0.043). Univariate and multivariable analyses revealed that higher GGT serum levels (p = 0.043, p = 0.005) and high histological grade (p = 0.029, p = 0.012) were independently associated with impaired OS, respectively. Higher pre-treatment GGT serum levels were independently associated with unfavorable prognosis in women with ULMS. Thus, GGT seems to be a useful novel biomarker in ULMS. |
format | Online Article Text |
id | pubmed-5028736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50287362016-09-26 Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma Schwameis, Richard Grimm, Christoph Brodowicz, Thomas Petru, Edgar Hefler-Frischmuth, Katrin Staudigl, Christine Reinthaller, Alexander Heinze, Georg Polterauer, Stephan Polterauer, Mariella Sci Rep Article Gamma-glutamyltransferase (GGT) is an established marker for proliferative/apoptotic balance and has been associated with cancer risk and prognosis. The aim of this study was to evaluate the value of pre-treatment GGT serum levels as prognostic biomarker in patients with primary uterine leiomyosarcoma (ULMS). Data of women with ULMS were extracted from a multi-center database. Pre-treatment GGT serum levels were measured and patients assigned to predefined GGT risk groups. GGT values were correlated with clinico-pathological parameters and univariate and multivariable survival analyses were performed. A total of 44 patients with ULMS were analyzed. Mean (SD) pre-therapeutic GGT serum level was 33.8 (39.8) U/L. In Figo Stage I versus II-IV mean (SD) GGT values were 28.8 (34.0) U/l and 43.5 (49.2) U/l, respectively (p = 0.25). Five-year overall survival (OS) rates in ULMS patients with normal low versus higher GGT levels were 70% and 37%, respectively (p = 0.043). Univariate and multivariable analyses revealed that higher GGT serum levels (p = 0.043, p = 0.005) and high histological grade (p = 0.029, p = 0.012) were independently associated with impaired OS, respectively. Higher pre-treatment GGT serum levels were independently associated with unfavorable prognosis in women with ULMS. Thus, GGT seems to be a useful novel biomarker in ULMS. Nature Publishing Group 2016-09-20 /pmc/articles/PMC5028736/ /pubmed/27646551 http://dx.doi.org/10.1038/srep33757 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Schwameis, Richard Grimm, Christoph Brodowicz, Thomas Petru, Edgar Hefler-Frischmuth, Katrin Staudigl, Christine Reinthaller, Alexander Heinze, Georg Polterauer, Stephan Polterauer, Mariella Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title | Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title_full | Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title_fullStr | Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title_full_unstemmed | Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title_short | Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
title_sort | gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028736/ https://www.ncbi.nlm.nih.gov/pubmed/27646551 http://dx.doi.org/10.1038/srep33757 |
work_keys_str_mv | AT schwameisrichard gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT grimmchristoph gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT brodowiczthomas gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT petruedgar gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT heflerfrischmuthkatrin gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT staudiglchristine gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT reinthalleralexander gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT heinzegeorg gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT polterauerstephan gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma AT polterauermariella gammaglutamyltransferaseasnovelbiomarkerinpatientswithuterineleiomyosarcoma |